Interleukins and interferons in mesenchymal stromal stem cell-based gene therapy of cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: England NLM ID: 9612306 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0305 (Electronic) Linking ISSN: 13596101 NLM ISO Abbreviation: Cytokine Growth Factor Rev Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Elsevier Science, c1996-
    • Subject Terms:
      Mesenchymal Stem Cells*/immunology ; Neoplasms*/therapy ; Neoplasms*/immunology ; Interferons* ; Genetic Therapy*/methods ; Interleukins*/therapeutic use ; Mesenchymal Stem Cell Transplantation*/methods; Humans ; Animals ; Tumor Microenvironment/immunology
    • Abstract:
      The tumor microenvironment is importantly shaped by various cytokines, where interleukins (ILs) and interferons (IFNs) shape the balance of immune activity within tumor niche and associated lymphoid organs. Their importance in activation and tuning of both innate and adaptive immune responses prompted their use in several clinical trials, albeit with limited therapeutic efficacy and risk of toxicity due to systemic administration. Increasing preclinical evidence suggests that local delivery of ILs and IFNs could significantly increase their effectiveness, while simultaneously attenuate the known side effects and issues related to their biological activity. A prominent way to achieve this is to use cell-based delivery vehicles. For this purpose, mesenchymal stromal stem cells (MSCs) are considered an almost ideal candidate. Namely, MSCs can be obtained in large quantities and from obtainable sources (e.g. umbilical cord or adipose tissue), their ex vivo expansion is relatively straightforward compared to other cell types and they possess very low immunogenicity making them suitable for allogeneic use. Importantly, MSCs have shown an intrinsic capacity to respond to tumor-directed chemotaxis. This review provides a focused and detailed discussion on MSC-based gene therapy using ILs and IFNs, engineering techniques and insights on potential future advancements.
      Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: Cell therapy; Gene therapy; Interferons; Interleukins; Mesenchymal stromal stem cells
    • Accession Number:
      9008-11-1 (Interferons)
      0 (Interleukins)
    • Publication Date:
      Date Created: 20240320 Date Completed: 20240620 Latest Revision: 20240620
    • Publication Date:
      20240621
    • Accession Number:
      10.1016/j.cytogfr.2024.03.002
    • Accession Number:
      38508954